Rumil

Phenobarbital

Method of action: Anticonvulsant, Antiepileptic, Antispasmodic, Hypnotic, Sedative

Treatment option: Absence Seizure, Insomnia, Seizure, Convulsions, Eclampsia, Epilepsy

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rumil

Rumil is the trade name for a medication containing the core active substance Phenobarbital, which is formally classified as a Central Nervous System (CNS) depressant. Phenobarbital is a member of the barbiturate drug class, a group of medications known for their profound effect on nerve activity. Phenobarbital is specifically distinguished as a long-acting barbiturate due to its sustained influence in the body. It is a synthetic substance chemically derived from barbituric acid.

Quick Facts

Property	Description
Active ingredient	Phenobarbital (Phenobarbitone)
Form	Tablet, Elixir, Injectable Solution
Pharmacological class	Barbiturate, CNS Depressant
General purpose	Neurological stabilization and calming
Origin	Synthetic substance

Composition, Forms, and General Purpose

Rumil is consistently manufactured as a single-ingredient product, containing only Phenobarbital or, when prepared for injection, its soluble salt, Phenobarbital Sodium. It is widely available in several versatile pharmaceutical preparations, including the solid tablet and liquid forms such as the elixir (oral solution), as well as a sterile injectable solution for both intravenous and intramuscular use. The fundamental action of this medicine is to stabilize neuronal membranes by enhancing the function of the body's natural inhibitory chemical, gamma-aminobutyric acid (GABA). This mechanism is key to achieving profound neurological control. For instance, its recognized purpose is to provide control in situations requiring sustained quieting of the nervous system, which establishes its role in managing unstable electrical signaling.

What side effects are possible with Rumil?

Possible Side Effects and Safety Information for Rumil

Rumil (active ingredient is a form of sodium oxybate) carries a Boxed Warning—the most serious level of safety warning issued by the FDA. This warning emphasizes the risks of Central Nervous System (CNS) depression and abuse/misuse.

Due to these serious risks, the medication is available only through a restricted program called a Risk Evaluation and Mitigation Strategy (REMS). This program ensures that patients, prescribers, and pharmacies are informed of the potential for significant CNS and respiratory depression, as well as the risks of addiction, misuse, and overdose.

Serious and Clinically Significant Adverse Reactions

CNS Depression: Can occur even at recommended doses and may manifest as clinically significant respiratory depression, sudden sleep onset, or blunting of alertness (obtundation). The risk is increased when used concurrently with alcohol or other sedative hypnotics, which is contraindicated.
Abuse and Misuse: The active substance has a high potential for abuse and is associated with CNS adverse reactions including seizure, coma, and death, particularly when used illicitly.
Psychiatric/Behavioral: Emergent or increased depression and suicidality have been reported. Other serious reactions include anxiety, confusion, and episodes of sleepwalking (parasomnias).

Common Adverse Reactions

The most frequently reported adverse reactions include nausea, dizziness, enuresis (bedwetting), headache, and vomiting.

Population-Specific Safety Notes

Geriatric Patients: Closer monitoring for impaired motor and cognitive function is necessary.
Hepatic Impairment: The drug is generally not recommended for initiation in patients with hepatic impairment due to increased drug exposure.

Patients must avoid operating hazardous machinery, including driving, for at least six hours after dosing, or until they know how the medicine affects them.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Rumil (Phenobarbital) is characterized by severe suppression of the central nervous system (CNS), which is explicitly described in official regulatory information. The documented clinical manifestations progress from somnolence, confusion, slurred speech, and ataxia to profound CNS depression and coma.

Life-Threatening Manifestations

Severe intoxication is officially associated with life-threatening outcomes, including severe respiratory depression leading to respiratory arrest, and cardiovascular instability characterized by profound hypotension and circulatory collapse. Subsequent complications such as pulmonary edema and secondary renal failure are also documented in regulatory labels. Risks are noted to be increased in the elderly and in patients with existing hepatic or renal impairment.

Required Emergency Actions

Regulatory guidance mandates that immediate medical attention must be sought for any suspected overdose. Emergency services must be contacted immediately if symptoms of severe toxicity, such as coma, severe respiratory compromise, or circulatory collapse, are observed. There is no specific antidote known to reverse the central nervous system depression caused by Phenobarbital. Management is defined as symptomatic and supportive, focusing on the maintenance of vital signs and procedures to enhance drug elimination, such as activated charcoal, forced alkaline diuresis, or hemodialysis for severe cases.

Therapeutic Uses of Rumil

What Rumil Treats: Main Uses and Benefits

The therapeutic application of Rumil (Phenobarbital) is used to address symptom clusters related to heightened neurological activity, which may be relevant across several conditions characterized by episodic or disruptive symptom patterns. The medication is applied across domains where additional symptomatic support is needed.

Rumil is commonly used in conditions presenting with acute episodes to help with managing symptoms of seizures (such as various epilepsy types and acute Status Epilepticus), managing symptoms associated with acute substance withdrawal syndromes, and for the short-term symptomatic relief of severe anxiety and tension. In specialized pediatric contexts, it is relevant for managing neonatal seizures and certain cases of hyperbilirubinemia.

“The overall benefit of Rumil generally supports the patient during difficult episodes by easing distress and assisting with maintaining functional stability.”

This supportive therapeutic benefit may assist with easing the overall symptom load associated with recurrent neurological episodes, contributing to patients coping more steadily with symptom fluctuations and supporting improved comfort during symptomatic periods.

Quick Fact: Relief for Neurological Symptoms
Primary Focus	Conditions involving significant, disruptive neurological excitability.
Key Benefit	Assisting with maintaining functional stability during symptomatic episodes.
Target Scenarios	Long-term symptomatic management of recurrent seizures and acute support during withdrawal.

Regulatory References

NIH StatPearls Monograph on Phenobarbital

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Rumil?

The official eligibility profile for the use of Rumil is defined by regulatory documents that stipulate specific patient groups for whom the medicine is either strictly prohibited or requires special caution.

Eligibility Status	Population Restriction	Regulatory Classification
Must Not Use (Contraindicated)	Known Hypersensitivity (severe allergic reaction) to the active substance or any excipients.	Contraindication
Must Not Use (Contraindicated)	Patients with severe heart problems, such as severe heart failure.	Contraindication
Must Not Use (Contraindicated)	Patients with a history of active or recurrent stomach/gastrointestinal ulcers and bleeding.	Contraindication
Restricted Use (Not Recommended)	Patients with severe liver disease or active liver disease.
Restricted Use
Restricted Use (Caution Required)	Patients with pre-existing kidney disease or hepatic impairment (requires dose adjustment and monitoring).	Caution/Warning
Restricted Use (Prohibited)	Pregnancy, particularly during the third trimester (definite evidence of risk to the developing baby).	Prohibited in 3rd Trimester
Restricted Use (Avoided)	Pediatric use (efficacy and safety may not be established).	Use Not Established

Use of this medicine is absolutely prohibited (contraindicated) for individuals with a known allergy to any of its components and for those with severe heart failure or active gastrointestinal bleeding/ulcers, per official labeling. For populations with existing liver or kidney disease, the medicine may be used, but only with caution and potentially adjusted dosing, as its use is officially not recommended in severe, active liver disease. Furthermore, the medicine is generally considered unsafe for use during pregnancy, especially in the third trimester, and its use in pediatric patients may be restricted due to insufficient data on safety and effectiveness in that age group.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Rumil (metronidazole) can interact with certain medicinal products and substances, which may increase the risk of serious side effects or change the effectiveness of the medications. Due to the potential for severe adverse reactions, specific combinations are contraindicated and must be completely avoided.

Contraindicated Combinations (Do Not Use):

Disulfiram: Taking Rumil with disulfiram, or within two weeks of stopping disulfiram, can lead to the development of psychotic reactions, including confusion.
Alcohol/Propylene Glycol: Consumption of alcohol or products containing propylene glycol during treatment and for at least three days after stopping Rumil is strictly contraindicated. This combination can trigger a disulfiram-like reaction, characterized by flushing, headaches, abdominal cramps, nausea, and vomiting.

Interactions Requiring Close Monitoring:

Interacting Product Category	Potential Effect and Requirement
Oral Anticoagulants (e.g., Warfarin)	Increased anticoagulant effect, raising the risk of bleeding. Requires careful and frequent monitoring of International Normalized Ratio (INR).
Lithium	Increased serum lithium concentrations, which can lead to toxicity. Requires monitoring of serum lithium and creatinine levels.
Busulfan	Increased busulfan blood concentrations. Concomitant use should generally be avoided; if necessary, busulfan doses may need adjustment based on plasma levels.
CYP Enzyme Inducers/Inhibitors	May alter the metabolism of Rumil or the co-administered drug, potentially leading to reduced effectiveness or increased side effects.
QT Prolonging Drugs	Caution is advised due to the potential for Rumil to prolong the QT interval, increasing the risk of cardiac rhythm changes.

Rumil has also been reported to interfere with certain blood chemistry laboratory tests, which should be considered when evaluating results. Patients with Cockayne syndrome should not take Rumil due to the risk of severe liver toxicity.

Mechanism of Action

Rumil is a co-formulation comprising two distinct active components: diclofenac and paracetamol (acetaminophen).

Diclofenac functions as a non-selective inhibitor of the cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. By competitively binding to the active site, diclofenac sterically impedes the conversion of arachidonic acid into prostanoid molecules, including prostaglandin E2 (PGE2). The resulting reduction in prostanoid biosynthesis modulates local cellular responses, diminishing the sensitization of peripheral nociceptors and lowering the threshold for thermal and chemical stimuli.

Paracetamol's mechanism is not fully elucidated but involves complex interactions within the central nervous system. It is considered a weak COX inhibitor, potentially exhibiting a higher functional selectivity for the COX-3 isoform or interacting with the endocannabinoid system. This central action contributes to the modulation of pain signal integration and the subsequent downstream systemic thermal regulation.

Collectively, the dual mechanism involves both the peripheral blockade of prostanoid synthesis and the central modulation of pain and thermoregulatory signaling pathways, resulting in systemic physiological modulation.

Dosage and Administration Information

How to Use Rumil: Administration Guidelines

The correct use of Rumil involves specific dosage forms, routes, and conditions for administration. These parameters provide the framework for how the medication is utilized in clinical settings.

Administration Scope

Attribute	Instruction Summary
Dosage Forms	Tablets, Capsules, Oral Solution, and Lyophilised Powder for Solution for Injection/Infusion.
Approved Routes	Oral use (tablets, solutions) and Parenteral use (Intravenous or Intramuscular Injection/Infusion).
Standard Dosing	Standard adult starting doses (e.g., 8 mg daily) and established maintenance doses (e.g., 16 mg to 24 mg daily).
Frequency	Typically administered either once or twice daily, depending on the formulation and strength.

Procedural and Population Rules

Administration conditions define how the medicine is taken. For certain oral formulations, Rumil is taken with food to manage absorption or tolerability. Conversely, other formulations may be taken without regard to meals. Solid forms, such as capsules or extended-release tablets, are swallowed whole and not crushed or chewed.

For injectable forms, preparation requires reconstitution and dilution with a specified solution (e.g., 0.9% Sodium Chloride) and administration over a set infusion time. Dosing adjustments are detailed for certain populations, such as a lower starting dose for patients with hepatic or renal impairment or specific weight-based dosing for pediatric use. If a dose is missed, the general approach is to skip the missed dose if it is close to the time for the next scheduled dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Rumil

Evidence for Use in Epilepsy and Seizure Management

Research has long examined the use of Rumil (Phenobarbital) in conditions characterized by fluctuating or episodic manifestations, specifically for long-term seizure management and the acute control of severe, prolonged seizures known as Status Epilepticus (SE). Studies included classic Randomized Controlled Trials (RCTs) and extensive observational studies that tracked outcomes over many years. Researchers examined how Rumil was associated with changes in seizure frequency and measured the time it took for seizures to stop during acute episodes.

The historical findings describe patterns observed in the studies related to seizure control in both adult and children populations. Evidence from the acute settings describes patterns observed in the studies where Rumil was monitored in protocols used for prolonged seizure episodes.

Evidence for Use in Acute Substance Withdrawal Syndromes

Rumil was studied for its use in managing symptoms associated with acute episodes, particularly severe Alcohol Withdrawal Syndrome. The research typically explores short-term symptom changes and often involves cohort studies and systematic reviews comparing Rumil-based protocols to those centered on other drug classes. These studies observed patients in hospital settings, measuring outcomes capturing phases of heightened symptom activity, such as hospital length of stay or assessing symptom severity using standardized clinical scales.

The data show patterns related to how quickly patients stabilized during the acute hospitalization period in the groups studied. The certainty surrounding this use is limited because much of the data comes from observational settings comparing different hospital protocols, rather than large-scale, dedicated, blinded RCTs focused only on Rumil.

What Remains Uncertain and Areas for Future Research

A primary limitation across the evidence base is the age of much of the comparative data, meaning comparative evidence is lacking against many modern drug classes. Long-term patterns of change are not fully established regarding developmental outcomes in children and the potential for cumulative effects in adults on maintenance therapy. Insight into long-term functional and neurological outcomes is still developing, especially in groups where current data remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Rumil (FAQ)

Q: What is the main reason Rumil is prescribed?

Studies and official information indicate that Rumil has been examined for use in long-term seizure management and for the acute control of severe, prolonged seizures. It has also been studied for the management of symptoms associated with acute Alcohol Withdrawal Syndrome.

Q: Does Rumil require a special diet or monitoring during its use?

Regulatory documents state that alcohol and products containing propylene glycol are strictly contraindicated for use with Rumil. Special monitoring is often required for patients who have existing conditions like severe heart, liver, or kidney problems, or for those taking certain interacting medications.

Q: Are there any long-term health concerns associated with using Rumil?

Official research evidence describes that the long-term patterns of change regarding cumulative effects in adults and developmental outcomes in children are not fully established. This means that insight into these long-term functional and neurological outcomes is still developing and subject to ongoing study.

Q: Can Rumil be taken at the same time as common over-the-counter pain relievers?

Caution is advised regarding potential interactions with other medicines, including those that can affect certain enzymes in the body (CYP enzyme inducers or inhibitors). This is due to the potential for certain over-the-counter products to fall into these categories, which may alter the effects of Rumil.

Q: Does Rumil interact with common herbal supplements like St. John's Wort or Ginkgo?

The official documents advise caution regarding co-administration with products, including herbal supplements, that act as CYP enzyme inducers or inhibitors. This is a warning related to the potential for these products to alter how Rumil is metabolized in the body.

Q: Can I use Rumil if I am pregnant or breastfeeding?

Regulatory guidance states that use of Rumil is generally prohibited during pregnancy, particularly in the third trimester, due to definite evidence of risk to the developing baby has been established.

Q: Can I take Rumil with my daily vitamin and mineral supplements?

Official information advises caution regarding potential interactions with any product, including supplements, that acts as a CYP enzyme inducer or inhibitor. This category of interaction could affect the concentration of Rumil in the body.

Q: Is Rumil a controlled substance?

The FDA has required a Boxed Warning for Rumil, which emphasizes risks of abuse and misuse. The medicine is available only through a restricted distribution program called a Risk Evaluation and Mitigation Strategy (REMS). The necessity of these warnings is tied to the potential for abuse and misuse.

Q: Does Rumil interact with grapefruit or grapefruit juice?

Official guidance warns against co-administration with substances classified as CYP enzyme inhibitors, which are known to potentially alter the way Rumil is processed in the body. This is a general caution regarding the drug’s metabolic pathway.

Q: Is Rumil only for short-term use?

Studies and official information describe patterns of use for both long-term seizure management and for short-term protocols used in acute conditions, such as substance withdrawal syndromes. This suggests both durations are addressed in the evidence base.

How should Rumil be stored and disposed of?

How to Store and Dispose of Rumil: Official Requirements

Official regulatory documents define the mandatory storage and disposal rules for Rumil.

Storage Conditions

Requirement	Official Instruction
Temperature	Store and transport refrigerated (2, C to 8, C).
Prohibited	Do not freeze.
Protection	Store and transport protected from light.
Child Safety	Keep out of the sight and reach of children.

⏰ Stability and Handling

The shelf life after first opening the immediate packaging is 10 hours when stored at room temperature. The product should not be mixed with any other medicinal product.